|
| |
 |
|
| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 14
| Issue : 10 | Page : 433-439 |
|
Favipiravir and its potentials in COVID-19 pandemic: An update
Dao Ngoc Hien Tam1, Ahmad T Qarawi2, Mai Ngoc Luu3, Morgan Turnage4, Linh Tran5, Gehad Mohamed Tawfik6, Le Huu Nhat Minh7, Nguyen Tien Huy8, Tatsuo Iiyama9, Kyoshi Kita8, Kenji Hirayama8
1 Online Research Club, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan; Asia Shine Trading & Service CO. LTD., Ho Chi Minh City 700000, Vietnam
2 Online Research Club, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan; Essen Healthcare, Bronx, New York 10461 USA
3 Online Research Club, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan; Department of Internal Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam
4 American University of the Caribbean, Cupecoy, Sint Maarten
5 Institute of Fundamental and Applied Sciences, Duy Tan University, Ho Chi Minh City 700000; Faculty of Natural Sciences, Duy Tan University, Da Nang City 550000, Vietnam
6 Online Research Club, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan; Department of Otorhinolaryngology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
7 Online Research Club, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan; Methodist Hospital, Merrillville, Indiana, United States
8 School of Tropical Medicine and Global Health, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
9 Department of International Trials, Center of Clinical Sciences, National Center for Global Health and Medicine (NCGM), Tokyo, Japan
| Date of Submission | 11-Jul-2021 |
| Date of Decision | 07-Sep-2021 |
| Date of Acceptance | 30-Sep-2021 |
| Date of Web Publication | 29-Oct-2021 |
Correspondence Address:
Nguyen Tien Huy
School of Tropical Medicine and Global Health, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523
Japan
 Source of Support: This study was funded by the Japan Agency for Medical Research and Development (AMED) under Grant Asian clinical trial network construction project (Number JP20lk0201001j0001). The funders had no role in preparation of the manuscript., Conflict of Interest: None  | 4 |
DOI: 10.4103/1995-7645.329005
The COVID-19 pandemic has caused millions of deaths and hundreds of millions of confirmed infections worldwide. This pandemic has prompted researchers to produce medications or vaccines to reduce or stop the progression and spread of this disease. A variety of previously licensed and marketed medications are being tested for the treatment and recurrence of SARS-CoV2, including favipiravir (Avigan). Favipiravir was recognized as an influenza antiviral drug in Japan in 2014, and has been known to have a potential in vitro activity against SARS-CoV-2, in addition to its broad therapeutic safety scope. Favipiravir was recently approved and officially used in many countries worldwide. Our review provides insights and up-to-date knowledge of the current role of favipiravir in the treatment of COVID-19 infection, focusing on pre-clinical and ongoing clinical trials, evidence of its efficacy against SARS-CoV-2 in COVID-19, side effects, anti-viral mechanism, and the pharmacokinetic properties of the drug in the treatment of COVID-19. Due to its teratogenic effects, favipiravir cannot be offered to expectant or pregnant mothers. The practical efficacy of such an intervention regimen will depend on its dose, treatment duration, and cost as well as difficulties in application. Keywords: Favipiravir; Avigan; COVID-19; SARS-CoV-2; Antiviral; Review; Efficacy
How to cite this article:
Tam DN, Qarawi AT, Luu MN, Turnage M, Tran L, Tawfik GM, Minh LH, Huy NT, Iiyama T, Kita K, Hirayama K. Favipiravir and its potentials in COVID-19 pandemic: An update. Asian Pac J Trop Med 2021;14:433-9 |
How to cite this URL:
Tam DN, Qarawi AT, Luu MN, Turnage M, Tran L, Tawfik GM, Minh LH, Huy NT, Iiyama T, Kita K, Hirayama K. Favipiravir and its potentials in COVID-19 pandemic: An update. Asian Pac J Trop Med [serial online] 2021 [cited 2023 Jun 2];14:433-9. Available from: https://www.apjtm.org/text.asp?2021/14/10/433/329005 |
| 1. Introduction | |  |
Over a year ago, the world started fighting coronavirus disease-2019 (COVID-19). No country was left unscathed. This new virus has unleashed a global crisis that we are still facing today. According to the World Health Organization (WHO) report, on August 10th, 2021, there have been 203 295 170 confirmed cases and 4 303 515 confirmed deaths worldwide. Maximum resources must be spent to fight the virus and its new strains, although each country has its own difficulties. The healthcare system bears a huge responsibility caused by the COVID-19 pandemic because of its transmission dynamics and polyphasic nature[1]. Therapeutic strategies such as antiviral drugs are essential to cope with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)[2]. When SARS-CoV-2 emerged, contact tracing and physical distancing began while trials for vaccines and therapeutic drugs were launched in many countries, including Japan. One of the most efficient approaches to discovering effective drugs is to test the efficacy of existing antiviral medications in treating related viral infections, and favipiravir (Avigan) seemed to be a potential candidate. Favipiravir is a synthetic prodrug, which acts as a competitive inhibitor of RNA-dependent RNA polymerase, thereby preventing the replication of RNA by negatively acting on genetic copying. It was first discovered while assessing the antiviral activity of chemical agents active against the influenza virus in the chemical library of Toyama Chemical Co., Ltd and was initially approved in Japan for the management of influenza infections in 2014. Favipiravir has activity against other RNA viruses such as the Ebola virus, Lassa virus, and a broad range of influenza viruses, including influenza A and B, A (H1N1) pdm09, A (H5N1), and A (H7N9) avian virus, as well as oseltamivir- and zanamivir-resistant influenza viruses, several agents of viral hemorrhagic fever and now SARS-CoV-2 in vitro[3],[4]. Favipiravir was approved and used in many countries including Bangladesh, China, Egypt, France, India, Italy, Japan, Kazakhstan, Moldova, Russia, Saudi Arabia, Turkey, Ukraine, the United Arab Emirates, and Uzbekistan for the treatment of SARS-CoV-2[5]. Many countries started using it as a potential treatment for COVID-19[6]. Although it is approved for use in such an urgent situation, large scale trials are necessary to evaluate its place in the further management of COVID-19. Eighty-five percent of COVID-19 patients have mild to moderate disease, which can be treated at home; consequently, this drug could benefit a considerable number of patients. Favipiravir dosing is either a loading dose of 1 800 mg in adults followed by 800 mg twice daily, or a 1 600 mg loading dose followed by 600 mg twice daily, up to 14 days[5],[7]. However, favipiravir cannot be administered to expectant mothers or those who may become pregnant due to its teratogenic effects. The benefits of antiviral medicines in the prevention of illness spreading on local outbreaks are yet to be revealed. Lastly, the practical efficacy of such an intervention regimen will depend on its dose, treatment duration, and cost as well as difficulties in application.
In this review, we overview the initial and current usage of favipiravir, its regulations for COVID-19 management in the world, current evidence of its safety and efficacy, as well as its mechanism of action against the virus.
| 2. Origin of favipiravir usage and countries currently approved or considered favipiravir in the treatment of COVID-19 | | |
In 2014, favipiravir was approved in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA) to treat novel or re-emerging influenza virus in cases where other antiviral agents were inactive or not efficient[8]. The initial dosage in adults is 1 600 mg twice a day, followed by 600 mg twice a day during five days of treatment.
At present, favipiravir is approved to treat COVID-19 in India, Indonesia, Russia, Malaysia, and China[9],[10],[11],[12],[13]. In India, favipiravir is intended to treat mild-to-moderate COVID-19 patients with the initial dosage of favipiravir 1 800 mg twice a day, followed by 800 mg twice a day for 14 days[9]. The manufacturer of favipiravir, Fujifilm Toyama Chemical Co. filed a registration for the approval of this drug in Japan in October 2020 with the hope of getting the license in December 2020[14]. However, the effectiveness of favipiravir could not be confirmed by clinical evidence and awaited additional data such as clinical trial results from the U.S.[15],[16]. According to the agency, clinicians in these studies were not blinded leading to a high risk of bias, making the results inconclusive[14]. Approval of favipiravir was pending additional clinical studies involving 270 patients in February 2021[17].
Till March 2021, 37 clinical trials were investigated for the efficacy or safety of favipiravir on clinicaltrials.gov [Supplementary Table 1]. The studies are conducted in several countries over the world including the U.S., the U.K., the Russian Federation, Canada, Egypt, Kuwait, China, Romani, Germany, Iran, Indonesia, Italy, Saudi Arabia, Mexico, Bangladesh, Bahrain, Hungary, Nepal, Thailand, Turkey, South Africa, and Kazakhstan.
| 3. Pre-clinical trials evidence against SAR-CoV-2 and other virus species | | |
The in vitro data of favipiravir against SAR-CoV-2 are limited, as only one study showed that the half-maximal effective concentration (EC50) of favipiravir against nCoV-2019 BetaCoV/ Wuhan/WIV04/2019 infected in Vero E6 cells was 61.88 μM[18]. Although this value was more promising than the results of other nucleoside analogs such as ribavirin and penciclovir, the value was still much higher than remdesivir which is an approved drug for COVID-19 treatment[18]. Interestingly, a derivative of favipiravir named cyanorona-20 was revealed to be more effective on a SARS-CoV-2 strain (BetaCoV/Hong Kong/VM20001061/2020) with EC50 of 0.45 μM which was 209 and 45 times more promising than favipiravir (EC50=94 μM) and remdesivir (EC50=20 μM)[19],[20].
Regardless, favipiravir is effective against influenza virus (type A, B, C) with the half-maximal inhibitory concentration (IC50) ranging from 0.014 to 0.550 μg/mL[21],[22]. Favipiravir showed its efficacy on Arenaviridae family (EC50=0.79-11.10 μg/mL), Bunyaviridae family (EC50=0.9-30.0 μg/mL), and Flaviviridae family (EC50=51.8 μg/mL for Yellow fever virus and EC50=3.5-3.8 μg/mL for Zika virus)[23],[24],[25],[26],[27].
| 4. Current clinical evidence of the efficacy of favipiravir in COVID-19 treatment | | |
The dosage of favipiravir applied in clinical trials of COVID-19 treatment is 1 600 mg twice a day (followed by 600 mg twice a day) or 1 800 mg twice a day (followed by 800 mg twice a day)[7],[28],[29],[30],[31]. However, the regimen of favipiravir of 1 600 mg twice a day (followed by 600 mg twice a day) for 10-14 days is more widely reported[7],[28],[32],[33].
Favipiravir treatment is associated with a shorter viral clearance time compared to the control (standard of care)[7],[30]. The standard of care in these studies included the provision of oxygen, rehydration, electrolyte correction, and drugs used for systemic symptoms (with the exception of antiviral treatments). The average time to viral clearance was 4 days in the favipiravir group compared to 11 days in the control groups[7]. Shorter viral clearance time was seen in another randomized clinical trial that showed that viral clearance was observed in 62.5% of COVID-19 patients on day 5 compared to 30% that received standard of care[30]. The rate of viral clearance of favipiravir (1 800 mg regimen) was similar in both early treatment groups (1 day after participation) and late treatment groups (6 days after participation) among asymptomatic and mild patients[31]. In particular, the viral clearance on day 6 was 66.7% and 56.1% in both early and late treatment groups. The fifty-nine percent logarithmic reduction of viral load by day 6 was insignificantly different between these two groups (94.4% and 78.8% in the early group and late group, respectively)[31]. However, favipiravir was still recommended to be used early (< 3 days) because it reduced mortality in severe cases. For instance, 17% of patients in early treatment died, which was much lower than the rate (38%) in the late treatment group. Also, time of defervescence was shorter in cases using early favipiravir[33],[34].
Besides, favipiravir treatment contributed to clinical improvement in mild and moderate COVID-19 patients[28],[29]. The clinical recovery rate of ordinary patients was 71.43% in the favipiravir group compared to 55.86% among control groups receiving arbidol (200 mg, three times daily)[26]. In patients with complications such as hypertension and/or diabetes, the treatment group saw a reduction in fever and cough[28]. In another study, the reduction in fever was 73.8% and 66.6% on day 7 in mild and moderate patients revealing its promising efficacy[29]. The defervescence (< 37 °C) in the treatment group (favipiravir) occurred within 2 days on average (for moderate patients) or 2.5 days (for mild patients) after treatment compared to 4 days on average in the control group[30],[31]. Regardless, the time to discharge of the favipiravir and control group was likely to be similar, which implied that the treatment did not reduce the hospital stay. For instance, 65% of patients treated with the 1 600 mg regimen, 85% of patients treated with the 1 800 mg regimen, and 85% of patients receiving standard of care were discharged by day15[30]. Only 40.1% and 60.3% of severe COVID-19 patients recovered after 7 days and 14 days of treatment, which revealed that treatment in severe patients was not promising[29].
In a case series of 11 severe patients in the intensive care unit (ICU) at the University of Tokyo Hospital, favipiravir was combined with nafamostat mesylate (0.2 mg/kg/day i.p.) and showed positive effects on the clinical conditions of the patients[35]. Seven of eight patients who required mechanical ventilation at the beginning of the treatment period did not require mechanical ventilation after an average of 16 days of treatment. One patient died under a do-not-resuscitate order. Two COVID-19 patients with comorbidities, such as diabetes mellitus, arterial hypertension, and obesity were transferred to the ICU during treatment with the favipiravir 1 600 mg regimen and later died[30].
Regarding the improvement shown by para-clinical measures, recovery measured by X-ray examinations or CT scans was observed in 91.43% and 90.0% patients, respectively, compared to standard of care [Table 1][7],[30]. | Table 1: Efficacy of favipiravir against SAR-CoV-2 in randomized clinical trials.
Click here to view |
| 5. Side effects of favipiravir on COVID-19 patients | | |
The most common adverse event was hyperuricemia which was seen in 69 of 82 patients (84.1%)[31]. The increase in alanine aminotransferase and serum triglyceride was reported as 8.5% and 11.0% in the study of Doi et al[31]. Other adverse events reported were fever, mild or moderate including diarrhea, nausea, vomiting, chest pain, and an elevation of liver transaminase levels, injuries of the kidney and liver, and rash[7],[30],[36]. There were fewer adverse events in the favipiravir groups than in those treated with lopinavir/ ritofavir (LPV/RTV)[7]. Tawara et al. reported one case of favipiravir medicinal fever[36], while only 4 patients treated with favipiravir suffered from diarrhea (2 patients), liver and kidney injury (1 patient), and other (1 patient); 25 patients treated with LPV/RTV had diarrhea, vomiting, nausea, rash, liver and kidney injury and others[7]. A meta-analysis also found that side effects in favipiravir groups and standard-of-care groups were insignificantly different[37]. In a prospective study of 40 patients, the same side effects were experienced and were self-limited. No patients discontinued favipiravir due to adverse events[38].
However, adverse reactions led to the discontinuation of 2 of 40 (5.0%) patients in the study of Ivashchenko et al[30]. In total, favipiravir has been shown its safety and tolerance when using in the short term[39]. However, there is a need for more evidence in terms of its efficacy in long-term usage. Until then, the drug should be used with caution in case the usage is outside of a clinical trial setting.
| 6. Antiviral mechanism of favipiravir | | |
Favipiravir showed its activity via several modes including inhibiting RNA-dependent RNA polymerase (RdRp), inhibiting the initiation and elongation of RNA formation, preventing the extension of RNA strand of virus, and causing lethal mutations [Figure 1].
The ability of inhibition of RdRp was shown on influenza H1N1 virus and H3N2 virus which led to the inhibition of viral replication[21],[40]. The inhibition type was competitive for the incorporation of ATP and GTP while mixed-type and noncompetitive types were observed for the incorporation of CTP and UTP, respectively[40],[41]. For norovirus RNA polymerase, favipiravir inhibited the initiation and elongation of RNA formation by competing mostly with ATP and GTP substrates[42]. Interestingly, this agent was barely effective at causing chain termination in noroviruses although this was evident in H1N1 virus by competing with ATP and GTP[42],[43]. The extension of RNA strand of influenza H1N1 virus was also stopped via incorporating into the RNA strand as substitutes of other ribonucleotides[40].
Another mode of action of favipiravir is to cause lethal mutations of viral RNA (norovirus, H1N1 virus, and SAR-CoV-2). These mutations are anticipated to increase replication errors, in other words, the extinction of viral replication or nonviable viral phenotypes[44]. The rise of mutation frequencies was noticed in the presence of favipiravir in which there were increases in transition rates of A-to-G and U-to-C in norovirus, H1N1 virus, H3N2 virus, and SAR-CoV-2 replication[40],[45],[46],[47].
The interaction between favipiravir and RNA polymerase was reported in in silico studies. In particular, hydrogen bonds were generated between favipiravir and RdRp of SAR-CoV-2 at amino acid residues ARG750 and ASP608[48],[49]. Nevertheless, the in silico analysis showed that there was no interaction between favipiravir and RdRp at the active sites in H1N1 virus[49]. This indicated that the inhibitory activity of favipiravir on the RNA polymerase of influenza virus was attributed to the lethal mutagenesis and replacement of substrates rather than the interaction with the enzyme at the active site.
| 7. Pharmacokinetic properties of favipiravir | | |
The oral bioavailability of favipiravir is about 97.6%[8]. The concentration of favipiravir in plasma reaches a peak after two hours of administration[50]. However, favipiravir is rapidly eliminated by the kidney before becoming an active form via phosphorylation in tissue. The binding of favipiravir and plasma protein is about 54%[51]. The free drug is metabolized into an inactive form mainly by aldehyde oxidase and partially by xanthine oxidase in the liver with a short half-life time of 2.0-5.5 hours[50].
| 8. Conclusions | | |
Recognizing the approved status, safety data, and primary measures of the effectiveness of favipiravir in COVID-19 throughout the world, rapid viral clearance, executive recovery rate, and availability as an oral medication with a validated safety profile make it a promising medication for the treatment of COVID-19 in mild and moderate patients. Further insights into the treatment efficacy, safety, and therapeutic role of favipiravir in the management process of COVID-19 should be established by ongoing clinical trials on favipiravir worldwide. The limitation of favipiravir in the management of the COVID-19 pandemic is that it cannot be offered to expectant or pregnant mothers due to its teratogenic consequences. Advantages of this antiviral intervention on local outbreaks in community transmission are yet to be deciphered. Lastly, the practical efficacy of such an intervention policy will depend on its dose, duration, and cost along with implementation difficulties.
Conflict of interest statement
All authors declare they have no conflict of interest.
Funding
This study was funded by the Japan Agency for Medical Research and Development (AMED) under Grant Asian clinical trial network construction project (Number JP20lk0201001j0001). The funders had no role in preparation of the manuscript.
Authors’ contributions
NTH developed the concept. DNHT, ATQ, MNL and NTH designed the study. DNT, ATQ, MNL, NTH, TI, KK and KH defined intellectual contents. ATQ, MNL, LT, GMT and LHNM conducted literature search. DNHT, ATQ, MNL, MT, LT, GMT, and LHNM performed data acquisition. DNHT, ATQ, MNL, MT, LT, GMT and LHNM prepared the manuscript. NTH, TI, KK and KH reviewed the initial manuscript. DNHT, ATQ, MNL and NTH edited manuscript to have the final one.
| References | | |
| 1. | Ahidjo BA, Loe MWC, Ng YL, Mok CK, Chu JJH. Current perspective of antiviral strategies against COVID-19. ACS Infect Dis 2020; 6(7): 1624-1634.  |
| 2. | Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020; 87(4): 281-286. |
| 3. | Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100(2): 446-454. |
| 4. | Liu J, Li H, Luo M, Liu J, Wu L, Lin X, et al. Lymphopenia predicted illness severity and recovery in patients with COVID-19: A single-center, retrospective study. PLoS One 2020; 15(11): e0241659. |
| 5. | Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India 2020; 76(4): 370-376. |
| 6. | Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis 2021; 102: 501-508. |
| 7. | Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering (Beijing) 2020; 6(10): 1192-1198. |
| 8. | Pharmaceutical and Food Safety Bureau Ministry of Health. Labour and welfare report on the deliberation results. 2014. [Online]. Available from: https://www.pmda.go.jp/files/000210319.pdf. [Accessed on 13 July 2021]. |
| 9. | |
| 10. | |
| 11. | |
| 12. | |
| 13. | |
| 14. | |
| 15. | |
| 16. | |
| 17. | |
| 18. | Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-271. |
| 19. | Rabie AM. Discovery of (E)-N-(4-cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (cyanorona-20): The first potent and specific anti-COVID-19 drug. Chemical Papers 2021; 75(9): 4669-4685. |
| 20. | Rabie AM. Cyanorona-20: The first potent anti-SARS-CoV-2 agent. Int Immunopharmacol 2021; 98: 107831. |
| 21. | Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005; 49(3): 981-986. |
| 22. | Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 2017; 93(7): 449-463. |
| 23. | Safronetz D, Rosenke K, Westover JB, Martellaro C, Okumura A, Furuta Y, et al. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci Rep 2015; 5(1): 1-11. |
| 24. | Gowen BB, Wong MH, Jung KH, Smee DF, Morrey JD, Furuta Y. Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Res 2010; 86(2): 121-127. |
| 25. | Buys KK, Jung KH, Smee DF, Furuta Y, Gowen BB. Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir. Antivir Chem Chemother 2011; 21(5): 193-200. |
| 26. | Tani H, Fukuma A, Fukushi S, Taniguchi S, Yoshikawa T, Iwata-Yoshikawa N, et al. Efficacy of T-705 (favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus. mSphere 2016; 1(1): e00061-15 |
| 27. | Zmurko J, Marques RE, Schols D, Verbeken E, Kaptein SJF, Neyts J. The viral polymerase inhibitor 7-deaza-2’-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl Trop Dis 2016; 10(5): e0004695-e0004695. |
| 28. | |
| 29. | |
| 30. | Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, et al. AVIFAVIR for treatment of patients with moderate COVID-19: Interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa1176. |
| 31. | Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother 2020; 64(12): e01897-01820. |
| 32. | Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, Ebeid FF, Abd El Ghafar MS, et al. Efficacy of favipiravir in COVID-19 treatment: A multi-center randomized study. Arch Virol 2021; 166(3): 949-954. |
| 33. | Karatas E, Aksoy L, Kilic PE, Dogru A, Ozaslan E. Early onset favipiravir saves lives. Research Square 2021. doi: 10.21203/rs.3.rs-142868/v1. (Preprint) |
| 34. | Fujii S, Ibe Y, Ishigo T, Inamura H, Kunimoto Y, Fujiya Y, et al. Early favipiravir treatment was associated with early defervescence in nonsevere COVID-19 patients. J Infect Chemother 2021; 27(7): 1051-1057. |
| 35. | Doi K, Ikeda M, Hayase N, Moriya K, Morimura N. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: A case series. Crit Care 2020; 24(1): 392. |
| 36. | Tawara J, Uehara T, Sakao S, Igari H, Taniguchi T, Kasai H, et al. Drug fever due to favipiravir administration for the treatment of a COVID-19 patient. Intern Med 2021; 60(7): 1115-1117. |
| 37. | Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: A rapid systematic review and meta-analysis. Virol J 2020; 17(1): 141. |
| 38. | Erdem HA, Korkmaz Ekren P, CaGlayan D, TaSbakan M, Yamazhan T, TaSbakan MS, et al. Treatment of SARS-cov-2 pneumonia with favipiravir: Early results from the Ege University cohort, Turkey. Turk J Med Sci 2020; 51(3): 912-920. |
| 39. | Malvy D, Taburet AM, de Lamballerie X, Mentre F, Extramiana F. The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers. PLoS Negl Trop Dis 2020; 14(6): e0008259. |
| 40. | Vanderlinden E, Vrancken B, Van Houdt J, Rajwanshi VK, Gillemot S, Andrei G, et al. Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis. Antimicrob Agents Chemother 2016; 60(11): 6679-6691. |
| 41. | Sangawa H, Komeno T, Nishikawa H, Yoshida A, Takahashi K, Nomura N, et al. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 2013; 57(11): 5202-5208. |
| 42. | Jin Z, Tucker K, Lin X, Kao CC, Shaw K, Tan H, et al. Biochemical evaluation of the inhibition properties of favipiravir and 2’-C-methyl-cytidine triphosphates against human and mouse norovirus RNA polymerases. Antimicrob Agents Chemother 2015; 59(12): 7504-7516. |
| 43. | Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5’-triphosphate towards influenza A virus polymerase. PloS One 2013; 8(7): e68347-e68347. |
| 44. | Eigen M. Error catastrophe and antiviral strategy. Proc Natl Acad Sci U S A 2002; 99(21): 13374-13376. |
| 45. | Arias A, Thorne L, Goodfellow I. Favipiravir elicits antiviral mutagenesis during virus replication in vivo. eLife 2014; 3: e03679-e03679. |
| 46. | Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 2013; 87(7): 3741-3751. |
| 47. | Shannon A, Selisko B, Le NTT, Huchting J, Touret F, Piorkowski G, et al. Rapid incorporation of favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commu 2020; 11(1): 4682-4682. |
| 48. | Mhatre S, Naik S, Patravale V. A molecular docking study of EGCG and theaflavin digallate with the druggable targets of SARS-CoV-2. Comput Biol Med 2021; 129: 104137. |
| 49. | Sada M, Saraya T, Ishii H, Okayama K, Hayashi Y, Tsugawa T, et al. Detailed molecular interactions of favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza virus polymerases in silico. Microorganisms 2020; 8(10): 1610. |
| 50. | Madelain V, Nguyen TH, Olivo A, Lamballerie X, Guedj J, Taburet AM, et al. Ebola virus infection: Review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet 2016; 55(8): 907-923. |
| 51. | Mentré F, Taburet AM, Guedj J, Anglaret X, Keïta S, Lamballerie X, et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis 2015; 15(2): 150-151. |
[Figure 1]
[Table 1]
| This article has been cited by | | 1 |
Identification of Z-Tyr-Ala-CHN2, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2 |
|
| Jordi Doijen, Koen Temmerman, Christel Van den Eynde, Annick Diels, Nick Van den Broeck, Michiel Van Gool, Inha Heo, Steffen Jaensch, Marleen Zwaagstra, Mayra Diosa Toro, Winston Chiu, Steven De Jonghe, Pieter Leyssen, Denisa Bojkova, Sandra Ciesek, Jindrich Cinatl, Lore Verschueren, Christophe Buyck, Frank Van Kuppeveld, Johan Neyts, Marnix Van Loock, Ellen Van Damme | | Microorganisms. 2023; 11(3): 717 | | [Pubmed] | [DOI] | | | 2 |
Effects of Vitamin C on the Oral-Nasal Mucosal Damage Caused by Favipiravir in Old and Young Rats |
|
| Yücel Kurt, Özlem Özmen | | Cureus. 2022; | | [Pubmed] | [DOI] | | | 3 |
Evaluation of the Effects of Favipiravir Combined with Vitamin C on Alveolar Bone in Rats |
|
| A. Lektemur Alpan, G. Torumtay Cin, Ö. Özmen, M. F. Dogan, Y. Sahin | | Journal of Evolutionary Biochemistry and Physiology. 2022; 58(2): 430 | | [Pubmed] | [DOI] | | | 4 |
STUDY OF CLINICAL AND PATHOGENETIC EFFECTS OF ANTI-VIRAL DRUG BASED ON FAVIPIRAVIR IN COMORBID PATIENTS WITH COVID-19 AT THE OUTPATIENT STAGE OF TREATMENT |
|
| L. A. Balykova, O. A. Radaeva, K. Ya. Zaslavskaya, Yu. A. Kostina, M. S. Iskandyarova, E. V. Negodnova, V. V. Eremeev, L. F. Sabirov, E. V. Semeleva | | Pharmacy & Pharmacology. 2021; 9(6): 454 | | [Pubmed] | [DOI] | |
|
 |
|
|
|
Search Pubmed for